163 related articles for article (PubMed ID: 37550186)
1. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
[No Abstract] [Full Text] [Related]
2. Mutational landscape of chronic myelomonocytic leukemia in Chinese patients.
Nie Y; Shao L; Zhang H; He CK; Li H; Zou J; Chen L; Ji H; Tan H; Lin Y; Ru K
Exp Hematol Oncol; 2022 May; 11(1):32. PubMed ID: 35610628
[TBL] [Abstract][Full Text] [Related]
3. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract][Full Text] [Related]
4. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
6. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
[TBL] [Abstract][Full Text] [Related]
7. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
[TBL] [Abstract][Full Text] [Related]
8. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Montalban-Bravo G; Kanagal-Shamanna R; Li Z; Hammond D; Chien K; Rodriguez-Sevilla JJ; Sasaki K; Jabbour E; DiNardo C; Takahashi K; Short N; Issa GC; Pemmaraju N; Kadia T; Ravandi F; Daver N; Borthakur G; Loghavi S; Pierce S; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
Br J Haematol; 2023 Nov; 203(4):581-592. PubMed ID: 37608562
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.
Patnaik MM; Tefferi A
Blood Cancer J; 2016 Feb; 6(2):e393. PubMed ID: 26849014
[TBL] [Abstract][Full Text] [Related]
11. Genomic Mutation Profiles of Patients with Acute Myeloid Leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract][Full Text] [Related]
12. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
Nagehan P; Sabbir M; Song J; Mohammad H
J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
[TBL] [Abstract][Full Text] [Related]
13. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiling reveals molecular subsets of
Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
[TBL] [Abstract][Full Text] [Related]
15. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
Giudice V; Serio B; Errichiello S; Ferrara I; Galdiero A; Bertolini A; Visconti R; De Novellis D; Guariglia R; Luponio S; Morini D; Della Corte AM; Sessa AM; Verdesca F; Langella M; Izzo B; Selleri C
Eur J Haematol; 2023 Nov; 111(5):729-741. PubMed ID: 37501402
[TBL] [Abstract][Full Text] [Related]
16. Integrated Clinical Genotype-phenotype Characteristics of STAT3-mutated Myeloid Neoplasms.
Ye MT; Zuo Z; Calin S; Ye F; He H; Kamata W; Yang Y; You MJ
Clin Cancer Res; 2024 May; ():. PubMed ID: 38767620
[TBL] [Abstract][Full Text] [Related]
17. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
Baumgartner F; Baer C; Bamopoulos S; Ayoub E; Truger M; Meggendorfer M; Lenk M; Hoermann G; Hutter S; Müller H; Walter W; Müller ML; Nadarajah N; Blombery P; Keller U; Kern W; Haferlach C; Haferlach T
Blood; 2024 Mar; 143(12):1139-1156. PubMed ID: 38064663
[TBL] [Abstract][Full Text] [Related]
18. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Yang L; Wei X; Gong Y
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38146893
[TBL] [Abstract][Full Text] [Related]
19. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.
Yang X; Zhao H; Wu H; Guo X; Jia H; Liu W; Wei Y; Can C; Ma D
Clin Chim Acta; 2024 Feb; 554():117789. PubMed ID: 38246208
[TBL] [Abstract][Full Text] [Related]
20. [MDS & CMML: Diagnostic and classification].
Wagner-Ballon O; Kosmider O
Bull Cancer; 2023 Nov; 110(11):1106-1115. PubMed ID: 37453834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
